12:00 AM
 | 
Apr 29, 2013
 |  BioCentury  |  Finance

Tecfidera upside?

Biogen ups guidance but stays mum on Tecfidera expectations
Tecfidera upside?

Investors liked what they heard about Biogen Idec Inc. (NASDAQ:BIIB) last week, sending the company's valuation up $2.4 billion by Friday's close.

On Monday, the stock rose $11.93 to $215.20, a $2.8 billion market cap gain, on early sales data reported by IMS Health for multiple sclerosis drug Tecfidera dimethyl...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >